Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

About MBX 1416 MBX 1416 is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist in development as a potential treatment for PBH. It was designed using the Company’s novel ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy. Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) ...